- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | CHOSA ONCOLOGY AB: CHOSA receives 94 tumour samples from US patients to validate Platin-DRP in lung cancer chemo-immunotherapy | - | Cision News | ||
| 27.08. | CHOSA ONCOLOGY AB: CHOSA Oncology accelerates value creation by entering into a commercially driven licensing agreement with Aida Oncology | 2 | Cision News | ||
| 15.07. | CHOSA ONCOLOGY AB: Chosa Oncology announces the result of exercise of warrants TO2 | 1 | Cision News | ||
| 13.07. | CHOSA ONCOLOGY AB: Members of executive management participate in the ongoing warrant - exercise ending tomorrow | 1 | Cision News | ||
| 10.07. | CHOSA ONCOLOGY AB: CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP | 1 | Cision News | ||
| 07.07. | Spotlight Stock Market: Market Notice 76/26 - Last day of trading in CHOSA Oncology AB's subscription option CHOSA TO 2 | 1 | Cision News | ||
| 01.07. | CHOSA ONCOLOGY AB: CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78 | 2 | Cision News | ||
| 23.06. | CHOSA ONCOLOGY AB: CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP | 1 | Cision News | ||
| CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 01.06. | CHOSA ONCOLOGY AB: CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study | 1 | Cision News | ||
| 01.06. | CHOSA ONCOLOGY AB: CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers | 4 | Cision News | ||
| 27.05. | Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB | 1 | Cision News | ||
| 06.05. | CHOSA ONCOLOGY AB: CHOSA Oncology publishes the Annual and Consolidated Financial Statements for the financial year 2025 | 1 | Cision News |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | +0,26 % | EQS-WpÜG: Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V. | EQS-WpÜG: Crown NL Bidco B.V. / Übernahmeangebot
Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V.
21.10.2026 / 23:30 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,360 | +0,09 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| COGENT BIOSCIENCES | 31,210 | 0,00 % | If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| SUMMIT THERAPEUTICS | 15,470 | 0,00 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MODERNA | 178,42 | -0,19 % | Sell the News: Warum starke Studiendaten den Moderna-Kurs crashen lassen | Die Moderna-Aktie stürzt trotz starker Studiendaten zum Krebsimpfstoff mit Merck um mehr als 25 Prozent ab. Analysten sehen eine klassische Sell-the-News-Reaktion nach monatelanger Kursrallye. Die Moderna-Aktie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,73 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,200 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| LYCIA THERAPEUTICS | 29,560 | -1,47 % | Lycia Therapeutics Prices Upsized $317.5 Mln IPO At $18/Share | WASHINGTON (dpa-AFX) - Lycia Therapeutics Inc. (LYCA) a clinical-stage biotechnology company developing treatments for autoimmune, inflammatory, and allergic diseases, said Thursday it priced... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,520 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| PRAXIS PRECISION MEDICINES | 252,88 | -0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 21,010 | +0,05 % | ArriVent to present phase 1 data for ARR-217 at ESMO | ||
| BOLT BIOTHERAPEUTICS | 6,250 | -0,32 % | Bolt Biotherapeutics, Inc. - 8-K, Current Report | ||
| TRAVERE THERAPEUTICS | 50,05 | 0,00 % | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,100 | -0,08 % | Harmony Biosciences: Mizuho bekräftigt Einstufung nach Verhandlungen im Patentrechtsstreit | ||
| RECURSION PHARMACEUTICALS | 3,695 | -0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
Das Unternehmen CHOSA ONCOLOGY AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,032 Euro und damit -1,22 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHOSA ONCOLOGY AB finden Sie auf Wallstreet Online.